Holen Sie sich die Stockscreener-App
18.80
4.47%
-0.88
Handel nachbörslich:
18.80
Crescent Biopharma Inc Aktie (CBIO) Neueste Nachrichten
Certain Warrants of Crescent Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026. - marketscreener.com
Certain Options of Crescent Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026. - marketscreener.com
CBIO: Major clinical milestones and global expansion set for 2027, with key data and partnerships advancing - TradingView
Crescent Biopharma at Cantor conference: global trial push By Investing.com - Investing.com Canada
Crescent Biopharma at Cantor conference: global trial push - Investing.com India
Two employees receive options tied to 58,650 Crescent Biopharma shares - Stock Titan
Crescent Biopharma (CBIO) Surges 8.9% to $20.20 as Biotech Momentum BuildsIV Contraction - vinanet.vn
Crescent Biopharma Announces September 2026 Investor Conference Presentations - quiverquant.com
Crescent Biopharma to Present at September Investor Conferences - GlobeNewswire
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Balyasny Asset Management L.P. Expands Stake in Crescent Biophar - GuruFocus
Crescent Biopharma (NASDAQ:CBIO) Stock Price Up 4.9%Should You Buy? - MarketBeat
Balyasny Asset Management (CBIO) discloses 6.03% Crescent Biopharma ownership - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Shares Gap DownShould You Sell? - MarketBeat
Crescent Biopharma (CBIO) Shares Dip 2.86% as Stock Approaches Key $16 Support LevelDay Trade Opportunities - vinanet.vn
Crescent Biopharma Ord Shs (CBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CBIO Q2 2026 Earnings: Narrower-Than-Expected Loss Buoys SharesRevenue Miss Report - vinanet.vn
Q3 EPS Forecast for Crescent Biopharma Lowered by Analyst - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
CRESCENT BIOPHARMA, INC. SEC Filing (Aug 3, 2026) - Stock Titan
Perceptive Advisors LLC Lowers Stake in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma (CBIO) Gets a Buy from Wedbush - The Globe and Mail
Crescent Biopharma Announces Q2 2026 Financial Results and Operational Update - Kalkine Media
Crescent Biopharma Reports Q2 2026 Results and Advances Clinical Development of CR-001, CR-002 and CR-003 - Quiver Quantitative
Crescent Biopharma: Q2 Earnings Snapshot - KING5.com
Crescent Biopharma posts $24.8 million Q2 net loss - Quiver Quantitative
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
CBIO Q1 2026 Earnings: EPS Beat Despite Pre-Revenue Status; Stock DeclinesEPS Guidance Update - vinanet.vn
Crescent Biopharma Ord Shs (CBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Crescent Biopharma Market Sentiment - Benzinga España
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Crescent Biopharma Ord Shs (CBIO) Institutional Confidence - TradingKey
CBIO Q1 2026 Earnings: Narrower Loss Surprises Analysts as Cash Management ImprovesEarnings Quality Score - vinanet.vn
CBIO|Crescent Biopharma Ord Shs|Price:16.300|Chg%:-0.730 - TradingKey
Crescent Biopharma (CBIO) Shares Dip 4.3% as Stock Pulls Back Toward Key SupportDefined Outcome ETF - dars.gov.et
Crescent Biopharma grants inducement stock options for 52,500 shares at $15.83 each - Bitget
Two Crescent Biopharma Employees Receive 52,500 Stock Options - Stock Titan
CBIO Options Volatility — NASDAQ:CBIO - TradingView
Jennison Associates LLC Invests $2.81 Million in Crescent Biopharma, Inc. $CBIO - MarketBeat
Fairmount Healthcare Fund II LP acquires 853,450 Crescent Biopharma shares for $12.38 million - Bitget
Fairmount Funds' $12 Million Bet on Crescent Biopharma: A Strong Signal Amidst Volatility - Kavout | AI
Insider fund at Crescent Biopharma (NASDAQ: CBIO) buys 1.38M shares, warrants - Stock Titan
Fairmount Funds holds 16.5% of Crescent Biopharma (CBIO) after July 2026 deal - Stock Titan
CBIO Q1 2026 Earnings: Better-than-Expected Loss as Biotech Continues DevelopmentInvestor Earnings Call - vinanet.vn
CBIO Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates Amid R&D ProgressBasic EPS Analysis - vinanet.vn
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma (CBIO) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Crescent Biopharma closes $143.7 million public offering - Investing.com
Crescent Biopharma closes $143.7 million public offering By Investing.com - Investing.com Nigeria
Crescent Biopharma (CBIO) Proxy filing Summary - Quartr
Press Release: Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Moomoo
Crescent Biopharma (CBIO) Bank of America Global Healthcare Conference 2026 Summary - Quartr
H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Hold Rating - Moomoo
Form 424B5 Crescent Biopharma Inc For: 15 July By Investing.com - Investing.com Canada
Crescent Bi raises up to $133.5M in registered offering of 8.09M shares and pre-funded warrants - TradingView
Crescent Biopharma (Nasdaq: CBIO) prices $125.0 million stock and warrant sale - Stock Titan
0.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):